Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids

European Respiratory Journal

Volumn 49, Issue 1, 2017, Pages

  Kunz, Lisette I Z ^a   Ten Hacken, N ^b   Lapperre, T S ^c   Timens, W ^e   Kerstjens, H A M ^b   Van Schadewijk, A ^a   Vonk, J M ^e   Sont, J K ^e   Snoeck Stroband, J B ^e   Postma, D S ^b   Sterk, P J ^f   Hiemstra, P S ^a   Kauffman, H F ^e   De Reus, D ^e   Boezen, H M ^e   Jansen, D F ^e   Barentsen, M D W ^e   Zeinstra Smit, M ^e   Luteijn, A J ^e   Van Der Molen, T ^e   Ter Veen, G ^e   Thiadens, H A ^e   Gosman, M M E ^b   Van Maaren, M S ^b   Veltman, C A ^b   Verbokkem, A ^b   Verhage, I ^b   Klooster, K ^b   Gast Strookman, J ^a   Janssen, K ^a   Rabe, K F ^a   Schrumpf, J A ^a   Smit Bakker, J ^a   Stolk, J ^a   Tire A C J A ^a   Van Der Veen, H ^a   Wijffels, M M E ^a   Willems, L N A ^a   Mauad, T ^g   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Dept of Allergology ^*  (Netherlands)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; SALMETEROL; BRONCHODILATING AGENT;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHUS BIOPSY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; FIBEROPTIC BRONCHOSCOPY; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; LONG TERM CARE; LONGITUDINAL STUDY; LUNG FUNCTION; LYMPHOCYTE COUNT; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT INFLAMMATION; SMOKING; SPUTUM CULTURE; TREATMENT WITHDRAWAL; AGED; BRONCHUS; CYTOLOGY; DRUG EFFECTS; FOLLOW UP; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; NETHERLANDS; NEUTROPHIL; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SPUTUM; STATISTICAL MODEL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; BRONCHI; BRONCHODILATOR AGENTS; FEMALE; FLUTICASONE; FLUTICASONE-SALMETEROL DRUG COMBINATION; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; LINEAR MODELS; MALE; MIDDLE AGED; NETHERLANDS; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; WITHHOLDING TREATMENT;

EID: 85008467288     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00839-2016     Document Type: Article

References (32)

1. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011;378:1015-1026.
2. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
3. Donaldson GC, Seemungal TAR, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004.
4. Singh D, Edwards L, Tal-Singer R, et al. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res 2010;11:77.
5. Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulm Dis 2012;7:587-595.
6. Barnes NC, Qiu YS, Pavord ID, et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;173:736-743.
7. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 2002;165:1592-1596.
8. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2009;151:517-527.
9. Reid DW, Wen Y, Johns DP, et al. Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related. Respirology 2008;13:799-809.
10. Bourbeau J, Christodoulopoulos P, Maltais F, et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007;62:938-943.
11. Verhoeven GT, Hegmans JP, Mulder PGH, et al. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness. Thorax 2002;57:694-700.
12. Ozol D, Aysan T, Solak ZA, et al. The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL-8 levels in stable COPD patients. Respir Med 2005;99:1494-1500.
13. Thompson AB, Mueller MB, Heires AJ, et al. Aerosolized beclomethasone in chronic bronchitis: improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis 1992;146:389-395.
14. Schermer TRJ, Hendriks AJC, Chavannes NH, et al. Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. Prim Care Respir J 2004;13:48-55.
15. Jarad NA, Wedzicha JA, Burge PS, et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. Respir Med 1999;93:161-166.
16. Van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1358-1363.
17. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285-1294.
18. Wouters EFM, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005;60:480-487.
19. Calverley PMA, Spencer S, Willits L, et al. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest 2003;124:1350-1356.
20. Kunz LIZ, Postma DS, Klooster K, et al. Relapse in FEV1 decline after steroid withdrawal in COPD. Chest 2015;148:389-396.
21. Rossi A, Guerriero M, Corrado A. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res 2014;15:77.
22. Van der Valk P, Monninkhof E, Van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: The COPE Study. Am J Respir Crit Care Med 2002;166:1358-1363.
23. Borrill Z, Roy K, Kolsum U, et al. Seretide withdrawal increases airway inflammation in moderate COPD patients. Eur J Clin Pharmacol 2009;65:1165-1166.
24. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
25. Lapperre TS, Postma DS, Gosman MME, et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax 2006;61:115-121.
26. Hsia CCW, Hyde DM, Ochs M, et al. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med 2010;181:394-418.
27. in't Veen JC, de Gouw HW, Smits HH, et al. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J 1996;9:2441-2447.
28. Barnes NC, Sharma R, Lettis S, et al. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J 2016;47:1374-1382.
29. Sont JK, de Boer WI, van Schadewijk WA, et al. Fully automated assessment of inflammatory cell counts and cytokine expression in bronchial tissue. Am J Respir Crit Care Med 2003;167:1496-1503.
30. Battaglia S, Mauad T, van Schadewijk AM, et al. Differential distribution of inflammatory cells in large and small airways in smokers. J Clin Pathol 2007;60:907-911.
31. Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD002991.
32. van den Berge M, Steiling K, Timens W, et al. Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity. Thorax 2014;69:14-23.